Revance Therapeutics

Revance Therapeutics

A company that develops and commercializes products for the treatment of dermatological diseases

Revance Therapeutics is a publicly held biotechnology company based in Newark, California. It specializes in developing neuromodulators for the treatment of asthetic and therapeutic conditions. Revance uses a proprietary stabilizing excipient peptide technology to create differentiated therapies.

Products

The company's lead product candidate, RT002 (DaxibotulinumtoxinA) for injection, is in clinical development for a broad range of aesthetic and therapeutic indications, including:

Glabellar Lines

The skin that sits between the eyebrows and above the nose. Face wrinkling is promoted by habitual facial expressions, aging, sun damage, smoking, poor hydration, and various other factors. Late stage clinical studies have produced positive results, with RT002 poised to progress to commercialization. Revance has also entered into an agreement with Fosun Pharmaceuticals for the exclusive rights to develop and commercialize RT002 in Mainland China, Hong Kong, and Macau.

Cervical Dystonia

An extremely painful, chronic neurological movement disorder where the neck and shoulder muscles contract involuntarily and contort, causing the head to twist or turn to the left, right, upwards, and/or downwards. RT002 has completed Phase 2 clinical trials for this condition.

Plantar Fasciitis

A subacute, degenerative process that often results in debilitating pain located in the heel and bottom of the foot. RT002 is entering Phase 2 clinical trials for this condition.

Hyperhidrosis

A skin disorder characterized by abnormally increased sweating in excess of that required for thermoregulation. RT002 in the pre-clinical stage for this condition.

Funding

Series A

On May 27, 2003 Revance Therapeutics completed their series A funding round with $1.8 million in funding from undisclosed investors.

Series B

On April 27, 2004 Revance Therapeutics completed their series B funding round with $13 million in funding from Essex Woodlands Health Ventures (lead investor), Vivo Capital, and Technology Partners.

Series C

On December 12, 2007 Revance Therapeutics completed their series C funding round with $43.5 million in funding from Medicis Pharmaceutical (lead investor), Vivo Capital, Technology Partners, Shepherd Ventures, Palo Alto Investors, and Essex Woodlands Health Ventures.

Series D

On January 4, 2010 Revance Therapeutics completed their series D funding round with $35 million in funding from Essex Woodlands Health Ventures (lead investor), Vivo Capital, Technology Partners, Shepherd Ventures, Palo Alto Investors, Pac-Link, and EDBI.

Series E

On April 2, 2013 Revance Therapeutics completed their series E funding round with $33 million in funding from NovaQuest, Essex Woodlands Health Ventures, and Delphi Ventures.

Timeline

April 2, 2013

Series E funding round

On April 2, 2013 Revance Therapeutics completed their series E funding round with $33 million in funding from NovaQuest, Essex Woodlands Health Ventures, and Delphi Ventures.

January 4, 2010

Series D funding round

On January 4, 2010 Revance Therapeutics completed their series D funding round with $35 million in funding from Essex Woodlands Health Ventures (lead investor), Vivo Capital, Technology Partners, Shepherd Ventures, Palo Alto Investors, Pac-Link, and EDBI.

December 12, 2007

Series C funding round

On December 12, 2007 Revance Therapeutics completed their series C funding round with $43.5 million in funding from Medicis Pharmaceutical (lead investor), Vivo Capital, Technology Partners, Shepherd Ventures, Palo Alto Investors, and Essex Woodlands Health Ventures.

April 27, 2004

Series B funding round

On April 27, 2004 Revance Therapeutics completed their series B funding round with $13 million in funding from Essex Woodlands Health Ventures (lead investor), Vivo Capital, and Technology Partners.

May 27, 2003

Series A funding round

On May 27, 2003 Revance Therapeutics completed their series A funding round with $1.8 million in funding from undisclosed investors.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Revance Therapeutics funding round, June 2011
45,000,000
June 10, 2011
Technology Partners
Revance Therapeutics Series D round
Series D round
36,236,932
November 11, 2010
Pac-Link
Revance Therapeutics Series E round
Series E round
33,000,000
April 2, 2013
Delphi Ventures
3 Results
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Abhay Joshi

COO

Austen Dake

Employee

Azhar Ghani

Employee

C. Richard Garfield

Employee

Caryn McDowell

Senior VP, General Counsel & Corporate Secretary

Dan Browne

Co-Founder, President & CEO

Joseph Di Lembo

Employee

Justin Ford

VP, Human Resources and Head of People

Luciana Miranda

Employee

Mahady Sarwary

Employee

Maria Millan

Employee

Max Lavie

Investor

Phil Kennedy

Employee

Sam Manoucheri

Employee

Tobin Schilke

CFO

Further reading

Title
Author
Link
Type
Date

Revance Therapeutics reaches licensing agreement with Fosun Pharmaceutical over botox formulation RT002

Sarah Toy

Web

Revance Therapeutics' Botox rival succeeds in late-stage trial

Manojna Maddipatla

Web

Why this East Bay drug maker's stock price nearly doubled last year

Ron Leuty

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
May 19, 2020
BioSpace
Revance Announces Agreement to Acquire HintMD and its Proprietary Fintech Platform for Aesthetic Practices - read this article along with other careers information, tips and advice on BioSpace

References

Page 1 of 2
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.